S. 1522 — A bill to require the Secretary of Health and Human Services to conduct a study on the designation of biosimilar biological products as interchangeable.

This bill requires the Food and Drug Administration to report on its designation of biosimilars as interchangeable, including the applicable standards, authorities, evidence, and other factors involved in such designations. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)